People · Operator
Named in public records as an officer, director or promoter · active 2011–2011 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $86.8M | $2.7B | 2011 |
Marc C. Tessier-Lavigne at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marc C. Tessier-Lavigne on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Doug Cole | 1 | 6 |
| John C. Maraganore | 1 | 2 |
| DAVID SCHENKEIN | 1 | 2 |
| Perry C. Karsen | 1 | 1 |
| Kevin C. Starr | 1 | 1 |
| Lewis C. Cantley | 1 | 1 |
| Duncan Higgons | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.